An American study group investigated the effects of the TEV-48125 antibody in the preventive treatment of chronic migraine and found that it may reduce the number of headache hours and number of moderate/severe headache days within a week, compared to placebo.
Chronic migraine (CM) is defined by headaches occurring on at least 15 days per month, with at least 8 days of migraine per month. Approximately 1% of adults suffer from CM, and it is the sixth most frequent cause of disability. The WHO classified CM as one of the most burdensome disabilities and people who suffer from CM are more likely to be unemployed, divorced and have psychological comorbidities. However, CM is often undertreated and only a third of these patients get preventive medication. Furthermore, less than 20% use preventive medication after a year, because of incomplete or slow-to-reach efficacy and poor tolerability.
In an article recently published in the American Academy of Neurology, an American study group did post hoc analysis on a previous study that assessed the efficacy of TEV-48125, a monoclonal antibody, in the preventive treatment of CM. They investigated the early onset of the beneficial effects of the treatment. 261 patients participated in the trial who had CM and were between 18 and 65 years of age. They were randomized to 3 groups: people in the first group got 900 mg TEV-48125 (225mg four times a month), participants in the second group got 675mg TEV-48125 once in the first month and then 225mg monthly, and the third was the placebo group. At baseline, participants had 162 headache hours per month and 17 migraine days per month. There was a significant decrease in the number of mean headache hours in the first two groups compared to placebo, with a higher decrease in the first group (900mg). The 900mg group first separated from placebo after 3 days, while the other treated group first separated on day 7. In addition, the benefit was extended through the second and third weeks of therapy. For moderate to severe headache days, the number of days were significantly reduced in the 900mg group after one week. While both treated groups showed significant improvement in the number of headache days per month compared to placebo by week-2, only the 900mg group showed significant improvement by week-3.
It seems that TEV-48125 is an effective preventive treatment of CM and that the beneficial effects may occur in both doses after a week of administration. These early-onset beneficial effects may increase the patients` adherence to the drug and result in a more effective preventive therapy of CM.
Written By: Dr. Fanni R. Eros